CNMD earnings: next report 2026-07-29, real EPS beat/miss history, analyst consensus Hold, P/E 23.70. Updated 2026-07-23.
CONMED (CNMD) Research Hub
CONMED (CNMD) trades on NYSE, US in the Healthcare (Medical - Devices) sector. As of 2026-09-11, shares last closed at 46.3 USD (-1.34%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 23.70, market cap 1.26B. This hub links to the full technical, earnings and options research available for CNMD.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Devices) |
|---|---|
| Exchange | NYSE, US |
| Last close | 46.3 USD (-1.34%) |
| 52-week range | 31.44 USD – 52.2 USD |
| Trend regime | Range |
| 14-day RSI | 35.3 (Bearish) |
| Trailing P/E | 23.70 |
| Market cap | 1.26B |
| Dividend yield | 0.48% |
| Next earnings | 2026-07-29 |
Available research for CNMD
Covered Call on CNMD: how it works, illustrative setup around the real 46.3 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CNMD: how it works, illustrative setup around the real 46.3 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CNMD: how it works, illustrative setup around the real 46.3 USD price, max profit/loss, breakeven and when to use it. Educational.
CNMD technical analysis: range, last 46.3 USD, RSI 35.3, 52w range 31.44 USD–52.2 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is CNMD in?
CONMED (CNMD) is classified under Healthcare (Medical - Devices), listed on NYSE, US.
Is CNMD in an uptrend or downtrend?
As of 2026-09-11, CNMD is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CNMD's trailing P/E ratio?
CNMD's trailing P/E is 23.70, with a market cap of 1.26B. See the earnings research page for full valuation detail.
When does CNMD next report earnings?
CNMD is next scheduled to report earnings on 2026-07-29, with a consensus EPS estimate of 1.1 USD.